Lanlan Gan
Daping, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A Critical Review of Cytochrome P450 Enzyme Inhibition by Herbal Phytochemicals: Implications for Drug Interaction Prediction and Herbal Safety.
Journal: Phytotherapy research : PTR
Published: December 18, 2025
Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.
Journal: Therapeutic advances in drug safety
Published: June 11, 2024
First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis.
Journal: Clinical Medicine Insights. Oncology
Published: May 15, 2024
Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States.
Journal: Frontiers in immunology
Published: April 30, 2024
Cholinesterase inhibitors-associated torsade de pointes/QT prolongation: a real-world pharmacovigilance study.
Journal: Frontiers in pharmacology
Published: November 24, 2023
Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment.
Journal: Pediatric neurology
Published: October 09, 2023
Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.
Journal: Frontiers in immunology
Published: May 18, 2023
Opportunities and challenges of pharmacovigilance in special populations: a narrative review of the literature.
Journal: Therapeutic advances in drug safety
Published: April 28, 2023
Carbon dots derived from pea for specifically binding with Cryptococcus neoformans.
Journal: Analytical biochemistry
Published: June 13, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026